Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours Β· Estimated delivery Aug 15 - Aug 20
162,163 Retatrutide (LY-3437943), a novel triple agonist developed by Eli Lilly that targets GLP-1R, GIPR and GCGR, has shown potential in preliminary clinical data for providing excellent blood sugar control and significant weight reduction
Ozempic and Wegovy both contain semaglutide and are manufactured by Novo Nordisk
If you are experiencing changes in sexual function while on GLP-1 therapy, schedule a consultation at our Lexington, Louisville, or London, KY location
Presented for research literature review only Balenovic D et al
Semaglutide is intended for specific medical conditions, like obesity or type 2 diabetes
There were only 364 reported semaglutide overdoses in 2020 and 196 in 2019, less than 10% of the number that occurred so far this year
